AEM vs EMN

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

Eastman Chemical Company exhibits significant fundamental deterioration, highlighted by a Piotroski F-Score of 4/9 (Stable but weak) and a severe earnings collapse of -67.5% YoY. While the current price of $72.00 sits near the Graham Number ($69.44), it trades at a massive premium to its growth-based intrinsic value of $28.70. The combination of negative revenue growth, a high dividend payout ratio (81.22%), and a bearish technical trend (0/100) suggests the stock is overvalued relative to its current trajectory.